Show simple item record

dc.contributor.authorLok, Kok-Hou
dc.contributor.authorWareham, Nicholas
dc.contributor.authorNair, Rajesh Sreedharan
dc.contributor.authorHow, Chee Wun
dc.contributor.authorChuah, Lay-Hong
dc.date.accessioned2022-05-06T23:30:46Z
dc.date.available2022-05-06T23:30:46Z
dc.date.issued2022-06
dc.identifier.issn1043-6618
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/336805
dc.description.abstractThe significant growth in type 2 diabetes mellitus (T2DM) prevalence strikes a common threat to the healthcare and economic systems globally. Despite the availability of several anti-hyperglycaemic agents in the market, none can offer T2DM remission. These agents include the prominent incretin-based therapy such as glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 inhibitors that are designed primarily to promote GLP-1R activation. Recent interest in various therapeutically useful gastrointestinal hormones in T2DM and obesity has surged with the realisation that enteroendocrine L-cells modulate the different incretins secretion and glucose homeostasis, reflecting the original incretin definition. Targeting L-cells offers promising opportunities to mimic the benefits of bariatric surgery on glucose homeostasis, bodyweight management, and T2DM remission. Revising the fundamental incretin theory is an essential step for therapeutic development in this area. Therefore, the present review explores enteroendocrine L-cell hormone expression, the associated nutrient-sensing mechanisms, and other physiological characteristics. Subsequently, enteroendocrine L-cell line models and the latest L-cell targeted therapies are reviewed critically in this paper. Bariatric surgery, pharmacotherapy and new paradigm of L-cell targeted pharmaceutical formulation are discussed here, offering both clinician and scientist communities a new common interest to push the scientific boundary in T2DM therapy.
dc.publisherElsevier BV
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleRevisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment.
dc.typeArticle
dc.publisher.departmentoffice of The School of Clinical Medicine
dc.date.updated2022-05-06T09:54:35Z
prism.endingPage106237
prism.number106237
prism.publicationDate2022
prism.publicationNamePharmacol Res
prism.startingPage106237
dc.identifier.doi10.17863/CAM.84224
dcterms.dateAccepted2022-04-22
rioxxterms.versionofrecord10.1016/j.phrs.2022.106237
rioxxterms.versionAM
dc.contributor.orcidWareham, Nicholas [0000-0003-1422-2993]
dc.identifier.eissn1096-1186
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMRC (MC_UU_00006/1)
cam.orpheus.success2022-05-06 - Embargo set during processing via Fast-track
cam.depositDate2022-05-06
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
rioxxterms.freetoread.startdate2023-04-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International